This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Deeg M, Ekelund M, Runge C.Adalimumab, etanercept or infliximab: what is the most cost-effective anti-TNF-alpha therapy in RA in a real-world setting. Value in Health 10: A244 (plus poster) abstr. PAR5, No. 6, Nov-Dec 2007
Rights and permissions
About this article
Cite this article
Etanercept of greater value than adalimumab or infliximab for RA. Pharmacoecon. Outcomes News 541, 2 (2007). https://doi.org/10.2165/00151234-200705410-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705410-00001